Kobayashi Profit Increases Due to Success in Generic Drug Business
This article was originally published in PharmAsia News
Executive Summary
For the third fiscal quarter, Kobayashi Pharmaceutical's profits increased by 2.6 percent even as its revenue decreased by 11 percent. President Yutaka Kobayashi credits the increase to its mergers and acquisitions strategies in its generic drug business. Kobayashi's generic, metabolic syndrome drug Naishitoru, launched in 2006, has brought in ¥3.5 billion ($32.7 million) in annual revenue. In 2005, Kobayashi bought the brand Inochi no Haha, a generic menopause drug with ¥0.3 billion ($2.8 million) in estimated annual revenue. In the first year following the purchase, Inochi no Haha surpassed the ¥1 billion in revenue. Already a major player in the generic drug industry, Kobayshi sees more space to grow in this area, and its M&A will not only focus on large companies, but also on mid-sized firms. (Click for more-Japanese language
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.